Table 1.

Descriptive analysis.

	n = 486
Antecedents, n (%)
Age, average (SD) (n = 486)	61 (14)
Female	194 (39.9)
Smoker (and ex-smoker)	111 (22.8)
Hypertension	205 (44.2)
Dyslipemia	140 (28.8)
Anxiety	56 (11.5)
Depression	27 (5.6)
Fibromyalgia/chronic fatigue	13 (2.7)
Obesity (BMI > 30)	153 (31.5)
Ischemic cardiopathy	14 (2.9)
Cardiac insufficiency	17 (3.5)
COPD	5 (1)
Chronic bronchitis	8 (1.6)
Asthma	4 (0.8)
Chronic renal disease	14 (2.9)
Diabetes	71 (14.6)
Diabetes with target organ damage	11 (2.3)
Age-adjusted Charlson Comorbidity Index, median (IQR)	2 (1–3)
Clinical evolution
PaO2/FiO2 at admission, median (IQR) (n = 385)	333 (300–373)
FiO2 at admission (%), median (IQR) (n = 486)	21 (21–21)
Minimum PaO2/FiO2, median (IQR) (n = 381)	300 (145–357)
Maximum FiO2 (%), median (IQR) (n = 486)	32 (21–60)
ARDS, n (%)	193 (39.7)
Intensive care unit, n (%)	100 (20.6)
CPAP-Helmet, n (%)	93 (19.1)
High flow oxygen, n (%)	26 (5.3)
Mechanical ventilation, n (%)	17 (3.5)
Hospital stay (days), median (IQR)	10 (6–15)
Stay in the Intensive Care Unit (days), median (IQR)	6 (4–10)
Analytical parameters, median (IQR)
Lymphopenia at admission (/μL) (n = 484)	990 (712–1320)
RCP at admission (mg/L) (n = 486)	64 (30–116)
Ferritin at admission (mcg/L) (n = 443)	482 (258–886)
IL-6 at admission (ng/L) (n = 285)	34 (16–60)
d-dimer at admission (ng/mL) (n = 431)	610 (380–1080)
Minimum lymphocytes during admission (/μL) (n = 484)	720 (520–1097)
Maximum RCP during admission (mg/L) (n = 485)	83 (40–136)
Maximum ferritin during admission (mcg/L) (n = 447)	655 (354–1189)
Maximum IL-6 during admission (ng/L) (n = 357)	38 (16–67)
Maximum d-dimer during admission (ng/mL) (n = 480)	940 (570–2120)
Treatment
Systemic corticosteroids during admission, n (%)	432 (88.9)
Total days of corticotherapy, median (IQR; n = 486)	36 (19–49)
SARS-CoV-2 vaccination after admission, n (%)	398 (81.9)